Biopharma Daily Stock Updates - 04/09/21

$XBI $129 -2%

$RDHL +9% Phase 2/3 COVID-19 Opaganib study unanimously recommended to continue. source

$CYDY +1% Leronlimab long-haulers trial closed with full enrollment. source

$SRNE -3% Received sNDA approval from FDA for ZTlido. source

$MRSN -2% Phase 2 UPLIFT trial of UpRi initiates patient dosing. source

$RUBY -1% Phase 1/2 trial of RTX-240 reported positive data and initiating new Phase 1 arm. source

$HGEN +3% Phase 1 ifabotuzumab results reported at AACR 2021. source

$GLSI +9% Phase 2b 5 year immune response reported 0% cancer recurrences. source